SEC Company Response from AMEDISYS INC (AMED) (CIK 0000896262) — Nov 24, 2020
AMEDISYS INC (AMED) (CIK 0000896262)
Date: Nov. 24, 2020 · CIK: 0000896262 · Accession: 0001193125-20-302605
AI Filing Summary & Sentiment
File numbers found in text: 000-24260
Referenced dates: November 19, 2020
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Filed February 19, 2020 Definitive Proxy Statement on Schedule 14A Filed April 24, 2020 File No. 000-24260
Dear Ms. Adams:
This letter is provided on behalf of Amedisys, Inc. (sometimes referred to herein as the “Company,” “Amedisys,” “we” or “our”), in response to the comment of the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) dated November 19, 2020 to Mr. Scott G. Ginn regarding the above-referenced Form 10-K for the fiscal year ended December 31, 2019 (the “Form 10-K”) and the Definitive Proxy Statement on Schedule 14A filed on April 24, 2020 (the “Proxy Statement”).
For ease of reference, we have reproduced your comment immediately preceding the Company’s response.
Form 10-K for the Fiscal Year Ended December 31, 2019
Definitive Proxy Statement on Schedule 14A
Proposal 1 – Election of Directors
Board Member Qualifications; Diversity, page 9
ALABAMA • FLORIDA • GEORGIA • LOUISIANA • MISSISSIPPI • TENNESSEE TEXAS WASHINGTON, D.C.
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
November 24, 2020
Page
Comment
1. The heading to this section includes diversity; however, there is no explicit discussion of whether or how the Board considers diversity in identifying director nominees. To the extent the Board considers diversity, in future filings so state and disclose the consideration given. Refer to Items 401(e) and 407(c)(2)(vi) of Regulation S-K.
Response
In response to the Staff’s comment, we respectfully advise the Staff that in future filings we will expand our disclosure of the consideration given by our Board of Directors to diversity in identifying nominees for director.
Please contact me at (615) 726-5768 if you have any questions regarding this response.
BAKER, DONELSON, BEARMAN,
CALDWELL & BERKOWITZ, PC
/s/ Lori B. Metrock
Lori B. Metrock
cc: Scott G. Ginn, Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
SHIPT TOWER
420 20TH STREET
NORTH
SUITE 1400
BIRMINGHAM, ALABAMA 35203
PHONE:
205.328.0480
FAX:
205.322.8007
www.bakerdonelson.com
LORI METROCK, SHAREHOLDER
Direct Dial: 615.726.5768
Direct Fax: 615.744.5768
E-Mail Address: lmetrock@bakerdonelson.com
November 24, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Attn.: Ms. Abby Adams
RE:
Amedisys, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2019
Filed February 19, 2020
Definitive Proxy Statement on Schedule 14A
Filed April 24, 2020
File No. 000-24260
Dear Ms. Adams:
This letter is provided on behalf of Amedisys, Inc. (sometimes referred to herein as the “Company,” “Amedisys,”
“we” or “our”), in response to the comment of the Staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) dated November 19, 2020 to Mr. Scott G. Ginn regarding the
above-referenced Form 10-K for the fiscal year ended December 31, 2019 (the “Form 10-K”) and the Definitive Proxy Statement on Schedule 14A filed on
April 24, 2020 (the “Proxy Statement”).
For ease of reference, we have reproduced your comment immediately preceding the
Company’s response.
Form 10-K for the Fiscal Year Ended December 31, 2019
Definitive Proxy Statement on Schedule 14A
Proposal 1 – Election of Directors
Board Member Qualifications; Diversity, page 9
ALABAMA • FLORIDA • GEORGIA
• LOUISIANA • MISSISSIPPI • TENNESSEE TEXAS
WASHINGTON, D.C.
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
November 24, 2020
Page
2
Comment
1. The heading to this section includes diversity; however, there is no explicit discussion of whether or how the Board considers diversity in identifying
director nominees. To the extent the Board considers diversity, in future filings so state and disclose the consideration given. Refer to Items 401(e) and 407(c)(2)(vi) of Regulation S-K.
Response
In response to the
Staff’s comment, we respectfully advise the Staff that in future filings we will expand our disclosure of the consideration given by our Board of Directors to diversity in identifying nominees for director.
Please contact me at (615) 726-5768 if you have any questions regarding this response.
BAKER, DONELSON, BEARMAN,
CALDWELL & BERKOWITZ, PC
/s/ Lori B. Metrock
Lori B. Metrock
cc:
Scott G. Ginn, Chief Financial Officer